Submission of Intimation of allotment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has allotted 4,00,000 equity shares (face value Rs. 10) at Rs. 20 each, including a Rs. 10 premium per share, following conversion of warrants held by non-promoter allottees. These warrants were originally issued on a preferential basis on 10th January 2025 (out of 1.50 crore warrants, with 72.65 lakh already converted earlier). The allotment is to three strategic non-promoter investors: Arpan Vipin Mantri (2,00,000 shares), Yellaboina Dhanraj (1,50,000 shares), and Sudhir Kumar Agarwal (50,000 shares). The company received Rs. 60 lakh (75% of the issue price) from this conversion. As a result, paid-up equity capital rose from Rs. 17.215 crore to Rs. 17.615 crore, with total shares increasing to 1,76,15,000.
Minor dilution of about 2.3% from this tranche (4 lakh out of 1.76 crore shares). The conversion strengthens the company's equity base by Rs. 60 lakh but does not materially alter shareholder value since warrants were already priced into the structure. Stock impact is likely negligible as this is a routine warrant-to-equity conversion.